Business Context and Reporting Period
Company: Outlook Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 5, 2019
Reporting Period: Event-based report regarding Nasdaq listing compliance status.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance status.
Material Changes
- Nasdaq Compliance: The Company received formal notification from the Hearings Department of The Nasdaq Stock Market LLC on March 4, 2019, confirming compliance with all applicable requirements for continued listing on The Nasdaq Capital Market.
- Minimum Bid Price: Specifically, the Company met the $1.00 minimum bid price requirement.
- Outcome: The hearing matter regarding the listing deficiency has been officially closed.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on March 5, 2019, announcing the resolution of the listing matter (filed as Exhibit 99.1).
Risks and Contingencies: No new risks or contingencies are disclosed in this specific filing. The primary risk of delisting due to non-compliance with the minimum bid price requirement has been resolved as of the report date.
Investor Verification Checklist
- Verify the current stock price to ensure continued compliance with the $1.00 minimum bid price requirement.
- Review the press release filed as Exhibit 99.1 for additional context on the listing status.
- Check subsequent filings for any new Nasdaq deficiency notices or financial updates.